| MPA (N=124) |
---|---|
Age (years) | 63.9±10.6 |
Gender (male/female) | 52/72 |
MPO-ANCA/PR3-ANCA | 117/7 |
BVAS | 15.9±5.7 |
General manifestation (Myalgia, Arthritis, Fever≥38°C, Weight loss≥2kg), n (%) | 68 (54.8%) |
Cutaneous involvement, n (%) | 8 (6.5%) |
Involvement of mucous membranes/eyes, n (%) | 2 (1.6%) |
Involvement of ear, nose, and throat (ENT), n (%) | 1 (0.8%) |
Pulmonary involvement, n (%) | 76 (61.3%) |
 Interstitial lung disease, n (%) | 59 (47.6%) |
 Alveolar hemorrhage, n (%) | 20 (16.1%) |
Cardiovascular involvement, n (%) | 15 (12.1%) |
Abdominal involvement, n (%) | 3 (2.4%) |
Nervous system involvement, n (%) | 21 (16.9%) |
Immunosuppressive treatment, n (%) | 93 (75.0%) |
Serum creatinine (μmol/L) | 353.0 (133.8-582.5) |
24h urinary protein (mg/24h) | 1608.0 (834.8-2552.2) |
Blood hemoglobin (g/L) | 88.6±19.6 |
Serum albumin (g/L) | 30.1±6.3 |
Erythrocyte sedimentation rate (mm/h) | 80.1±34.1 |
Serum C-reactive protein (mg/L) | 71.5 (21.7-98.9 ) |
Coronary heart disease | 12 (9.7%) |
Heart failure | 7 (5.6%) |
Cerebrovascular disease | 0 |
Chronic obstructive pulmonary disease | 6 (4.8%) |
Peripheral vascular disease | 0 |
Liver disease | 2 (1.6%) |
Peptic ulcer disease | 9 (7.3%) |
Diabetes | 13 (10.5%) |